EX-99.1
2
v374081_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
AMRI Completes Acquisition
of Cedarburg Pharmaceuticals, Inc.
Albany, NY (April
4, 2014) - AMRI (NASDAQ: AMRI) today announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals,
Inc.
Cedarburg, whose
capabilities both augment and complement those of AMRI, is a contract developer and manufacturer of technically complex active
pharmaceutical ingredients (API's) for both generic and branded customers. The transaction is consistent with AMRI's
strategy to be the preeminent supplier of custom and complex drug development services and product to both the branded and generic
pharmaceutical industry. Customers will benefit from access to a greater breadth of resources, including development of complex
API, expanded scale-up capabilities and large scale manufacturing in lower cost environments.
Total consideration
paid was $41 million, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. The acquisition
is expected to add between $13 and $14 million to AMRI's revenue in 2014. AMRI anticipates full year run-rate synergies of
approximately $1.5 million of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI's
2014 adjusted diluted EPS in the range of $0.06 to $0.07 per share. Items excluded from non-GAAP financial results are expected
to include all transaction-related costs, including amortization of intangible assets.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial
measures, such as EBITDA and adjusted diluted EPS, which are adjusted to exclude, among other things, the impact of interest income
and expense, depreciation and amortization expense, and income tax expense or benefit. We exclude these items from the non-GAAP
financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures,
as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial
measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in
this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without
the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance,
especially when comparing such results to prior periods or forecasts. Non-GAAP results also allow investors to compare the Company's
operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP
financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations
prepared in accordance with GAAP. Cedarburg's contribution to AMRI's adjusted diluted EPS is only provided on a non-GAAP
basis. It is not feasible to provide reconciliation to the most comparable projected U.S. GAAP measure because the excluded items
are difficult to predict and estimate and are primarily dependent on future events.
About AMRI
Albany Molecular Research, Inc. (AMRI) is
a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing
services. For over 22 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone
tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States,
Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers
with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully
partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information
about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
Forward-looking Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These
statements include, but are not limited to, statements regarding the acquisition of Cedarburg Pharmaceuticals, Inc., Cedarburg's
projected contribution to AMRI's adjusted diluted EPS, the potential synergies associated with the transaction, the potential
impact on AMRI's operations and financial results, statements regarding the strength of the company's business and
prospects, statements regarding the actions taken to reduce cost and improve operating performance, and statements concerning the
company's momentum and long-term growth, including expected results for 2014 and possible investment opportunities. Readers
should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from
such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not
be within the company's control. Factors that could cause such differences include, but are not limited to, the ability of
the Company to effectively integrate Cedarburg's business; possible negative impacts to the revenue expected to be received
by Cedarburg following the closing of the transaction; trends in pharmaceutical and biotechnology companies' outsourcing
of chemical research and development, including softness in these markets; sales of Allegra® and the impact of the "at-risk"
launch of generic Allegra®, the OTC conversion of Allegra® and the generic and OTC sales of Allegra in Japan on the company's
receipt of significant royalties under the Allegra® license agreement; the success of the sales of other products for which
the company receives royalties; the risk that the company will not be able to replicate either in the short or long term the revenue
stream that has been derived from the royalties payable under the Allegra® license agreements; the risk that clients may terminate
or reduce demand under any strategic or multi-year deal; the company's ability to enforce its intellectual property and technology
rights; the company's ability to obtain financing sufficient to meet its business; the company's ability to successfully
comply with heightened FDA scrutiny on aseptic fill/finish operations; the results of further FDA inspections; the company's
ability to effectively maintain compliance with applicable FDA and DEA regulations; the company's ability to integrate past
or future acquisitions and make such acquisitions accretive to the company's business model; the company's ability
to take advantage of proprietary technology and expand the scientific tools available to it; the ability of the company's
strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company's Annual Report
on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 17, 2014, and the
company's other SEC filings. Potential increases in AMRI's adjusted diluted EPS, potential synergies available following
closing of the pending transaction and other forward looking information offered by senior management today represent a point-in-time
estimate and are based on information as of the date of this press release. Senior management has made numerous assumptions in
providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those
noted above, may cause actual results to differ materially from the guidance provided. The company expressly disclaims any current
intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect
future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements
contained in this press release.
Contacts:
Investors: Michael Nolan, AMRI Chief Financial Officer, 518-512-2261
Media: Gina Rothe, AMRI Communications, 518-512-2512

EX - 99 . 1 2 v374081 _ ex99 - 1 . htm EXHIBIT 99 . 1 Exhibit 99 . 1 AMRI Completes Acquisition of Cedarburg Pharmaceuticals , Inc . Albany , NY ( April 4 , 2014 ) - AMRI ( NASDAQ : AMRI ) today announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals , Inc . Cedarburg , whose capabilities both augment and complement those of AMRI , is a contract developer and manufacturer of technically complex active pharmaceutical ingredients ( API 's ) for both generic and branded customers . The transaction is consistent with AMRI 's strategy to be the preeminent supplier of custom and complex drug development services and product to both the branded and generic pharmaceutical industry . Customers will benefit from access to a greater breadth of resources , including development of complex API , expanded scale - up capabilities and large scale manufacturing in lower cost environments . Total consideration paid was $ 41 million , including assumption of certain liabilities . AMRI financed the transaction with cash on hand . The acquisition is expected to add between $ 13 and $ 14 million to AMRI 's revenue in 2014 . AMRI anticipates full year run - rate synergies of approximately $ 1.5 million of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI 's 2014 adjusted diluted EPS in the range of $ 0.06 to $ 0.07 per share . Items excluded from non - GAAP financial results are expected to include all transaction - related costs , including amortization of intangible assets . Use of Non - GAAP Financial Measures This press release contains non - GAAP financial measures , such as EBITDA and adjusted diluted EPS , which are adjusted to exclude , among other things , the impact of interest income and expense , depreciation and amortization expense , and income tax expense or benefit . We exclude these items from the non - GAAP financial measures because they are outside our normal operations . There are limitations in using non - GAAP financial measures , as they are not prepared in accordance with generally accepted accounting principles , and may be different than non - GAAP financial measures used by other companies . In particular , we believe that the inclusion of supplementary non - GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often - one - time charges , and is consistent with how management measures and forecasts the Company 's performance , especially when comparing such results to prior periods or forecasts . Non - GAAP results also allow investors to compare the Company 's operations against the financial results of other companies in the industry who similarly provide non - GAAP results . The non - GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP . Cedarburg 's contribution to AMRI 's adjusted diluted EPS is only provided on a non - GAAP basis . It is not feasible to provide reconciliation to the most comparable projected U . S . GAAP measure because the excluded items are difficult to predict and estimate and are primarily dependent on future events . About AMRI Albany Molecular Research , Inc . ( AMRI ) is a global contract research and manufacturing organization offering customers fully integrated drug discovery , development and manufacturing services . For over 22 years , AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges . This experience , a track record of success and locations in the United States , Europe and Asia now provides our customers with SMARTSOURCING ™ , a full range of value - added opportunities providing customers with informed decision - making , enhanced efficiency and more successful outcomes at all stages of the pipeline . AMRI has also successfully partnered R & D programs and is actively seeking to out - license its remaining programs for further development . For more information about AMRI , please visit our website at www.amriglobal.com or follow us on Twitter ( @ amriglobal ) . Forward - looking Statements This press release includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties . These statements include , but are not limited to , statements regarding the acquisition of Cedarburg Pharmaceuticals , Inc . , Cedarburg 's projected contribution to AMRI 's adjusted diluted EPS , the potential synergies associated with the transaction , the potential impact on AMRI 's operations and financial results , statements regarding the strength of the company 's business and prospects , statements regarding the actions taken to reduce cost and improve operating performance , and statements concerning the company 's momentum and long - term growth , including expected results for 2014 and possible investment opportunities . Readers should not place undue reliance on our forward - looking statements . The company 's actual results may differ materially from such forward - looking statements as a result of numerous factors , some of which the company may not be able to predict and may not be within the company 's control . Factors that could cause such differences include , but are not limited to , the ability of the Company to effectively integrate Cedarburg 's business ; possible negative impacts to the revenue expected to be received by Cedarburg following the closing of the transaction ; trends in pharmaceutical and biotechnology companies ' outsourcing of chemical research and development , including softness in these markets ; sales of Allegra ® and the impact of the " at - risk " launch of generic Allegra ® , the OTC conversion of Allegra ® and the generic and OTC sales of Allegra in Japan on the company 's receipt of significant royalties under the Allegra ® license agreement ; the success of the sales of other products for which the company receives royalties ; the risk that the company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra ® license agreements ; the risk that clients may terminate or reduce demand under any strategic or multi - year deal ; the company 's ability to enforce its intellectual property and technology rights ; the company 's ability to obtain financing sufficient to meet its business ; the company 's ability to successfully comply with heightened FDA scrutiny on aseptic fill / finish operations ; the results of further FDA inspections ; the company 's ability to effectively maintain compliance with applicable FDA and DEA regulations ; the company 's ability to integrate past or future acquisitions and make such acquisitions accretive to the company 's business model ; the company 's ability to take advantage of proprietary technology and expand the scientific tools available to it ; the ability of the company 's strategic investments and acquisitions to perform as expected , as well as those risks discussed in the company 's Annual Report on Form 10 - K for the year ended December 31 , 2013 as filed with the Securities and Exchange Commission on March 17 , 2014 , and the company 's other SEC filings . Potential increases in AMRI 's adjusted diluted EPS , potential synergies available following closing of the pending transaction and other forward looking information offered by senior management today represent a point - in - time estimate and are based on information as of the date of this press release . Senior management has made numerous assumptions in providing this guidance which , while believed to be reasonable , may not prove to be accurate . Numerous factors , including those noted above , may cause actual results to differ materially from the guidance provided . The company expressly disclaims any current intention or obligation to update the guidance provided or any other forward - looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward - looking statements contained in this press release . Contacts : Investors : Michael Nolan , AMRI Chief Financial Officer , 518 - 512 - 2261 Media : Gina Rothe , AMRI Communications , 518 - 512 - 2512
O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O